Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
11:55:00 2026-10-07 EDT
|
After hours 15:17:26 | |||
| 76.52 EUR | +0.50% |
|
76.56 | +0.05% |
| 10-02 | Eurofins Completes Sale of MET Labs Business | MT |
| 10-01 | UL Solutions Completes Acquisition of Eurofins' Electrical, Electronics Business | MT |
| Market Cap | 13.22B 14.79B 12.33B 11.2B 21.1B 1,431B 21.25B 148B 57.9B 728B 55.54B 54.34B 2,340B | P/E 2026 * |
25.4x | P/E 2027 * | 20.1x |
|---|---|---|---|---|---|
| Enterprise Value | 16.66B 18.65B 15.55B 14.12B 26.59B 1,804B 26.79B 187B 72.98B 917B 70.01B 68.5B 2,949B | EV / Sales 2026 * |
2.21x | EV / Sales 2027 * | 2.05x |
| Free-Float |
60.39% | Yield 2026 * |
1.05% | Yield 2027 * | 1.19% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
London S.E.
| 0MV5 | Delayed | |
|
OTC Markets
| ERFSF | Delayed | |
|
Tradegate
| ESF0 | Real-time | |
|
Xetra
| ESF0 | Delayed | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript: Eurofins Scientific SE
| 1 day | +0.50% | ||
| 1 week | +2.03% | ||
| Current month | +2.03% | ||
| 1 month | +6.87% | ||
| 3 months | +11.03% | ||
| 6 months | +17.65% | ||
| Current year | +22.63% |
| 1 week | 73.3 |  | 78.56 |
| 1 month | 68.38 | | 79.22 |
| Current year | 56.84 | | 79.22 |
| 1 year | 54.86 | | 79.22 |
| 3 years | 39.47 | | 79.22 |
| 5 years | 39.47 | | 118.12 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/27/26 | Buy | 700 | 0.0004% | |||
| 4/19/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 4/19/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.50% | +2.03% | +22.90% | +47.04% | 14.89B | |
| +4.16% | +4.16% | +49.37% | +94.17% | 74.69B | |
| +0.46% | -0.97% | +23.51% | +79.57% | 58.81B | |
| +0.17% | +0.35% | +6.85% | +34.55% | 48.45B | |
| +0.17% | -3.07% | +327.21% | +681.12% | 42.84B | |
| -0.74% | -3.86% | +28.68% | +29.53% | 42.79B | |
| -0.01% | -0.52% | +6.57% | +110.69% | 41.25B | |
| -0.11% | +1.96% | +9.19% | +52.66% | 31.13B | |
| -2.07% | +1.16% | +35.00% | +26.28% | 30.28B | |
| +0.25% | -2.30% | -9.45% | -12.14% | 24.05B | |
| Average | +0.24% | -0.24% | +49.98% | +114.35% | 40.92B | |
| Weighted average by Cap. | +0.61% | -0.52% | +54.69% | +125.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.53B 8.43B 7.03B 6.39B 12.03B 816B 12.12B 84.48B 33B 415B 31.66B 30.97B 1,334B | 7.94B 8.89B 7.41B 6.73B 12.68B 860B 12.77B 89.06B 34.79B 437B 33.38B 32.66B 1,406B |
| Net income | 531M 594M 495M 450M 847M 57.48B 854M 5.95B 2.33B 29.23B 2.23B 2.18B 93.97B | 660M 738M 615M 559M 1.05B 71.42B 1.06B 7.4B 2.89B 36.32B 2.77B 2.71B 117B |
| Net Debt | 3.44B 3.86B 3.21B 2.92B 5.5B 373B 5.54B 38.62B 15.09B 190B 14.47B 14.16B 610B | 3.1B 3.47B 2.89B 2.63B 4.95B 336B 4.98B 34.76B 13.58B 171B 13.03B 12.74B 549B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-07 | €76.52 | +0.50% | 262,318 |
| 26-10-06 | €76.14 | +0.79% | 312,225 |
| 26-10-05 | €75.54 | +0.91% | 412,968 |
| 26-10-02 | €74.86 | +0.43% | 416,371 |
| 26-10-01 | €74.54 | -0.61% | 496,921 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
